Trials / Completed
CompletedNCT02087098
A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics
Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare™ (Solifenacin) From Other Antimuscarinics
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (actual)
- Sponsor
- Astellas Pharma Europe B.V. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 12 month non-interventional study with solifenacin succinate, evaluating the effect of solifenacin on quality of life (QoL) of patients previously treated with antimuscarinics (Males and Females with Overactive Bladder (OAB) symptoms withdrawing their treatment with antimuscarinics because of safety and/or efficacy reasons) - measured by Perception of Treatment Satisfaction (TS-VAS) and to evaluate the effect of solifenacin on quality of life measured by Over Active Bladder-q Short Form (OAB-q SF), EuroQol Group scoring system (EQ-5D-5L).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Solifenacin | Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-03-14
- Last updated
- 2016-09-13
Locations
60 sites across 1 country: Czechia
Source: ClinicalTrials.gov record NCT02087098. Inclusion in this directory is not an endorsement.